Navigation Links


Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study

7/28/2015
MORRISTOWN, N.J. , July 28, 2015  Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis.  The study, conducted in the United Kingdom , is a double-blind, two-way cross-over des... [Comments]

Revolutionary Bone Graft Exceeds Expectations

7/28/2015
NEWPORT BEACH, Calif. , July 28, 2015 BioStructures, LLC, a privately held orthobiologics company, announced that it has hit a milestone of 4,000 implantations of Signafuse® Bioactive Bone Graft Putty. Signafuse was FDA 510(k) cleared in early 2014 as a bone void filler indicated for standalone use in posterolateral spine fusion procedures.  This is a dist... [Comments]

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A

7/28/2015
KING OF PRUSSIA, Pa. , July 28, 2015 CSL Behring announced today that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In the pivotal clinical trial, rVIII-SingleChain met all primary endpoint... [Comments]

Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology

7/28/2015
QUEBEC CITY , July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) (TSX: AEZ) (the "Company") today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology (collectively, the "Optionee"), an option to license the Company's live recombinant oral allogenic tumor... [Comments]

United Therapeutics Corporation Reports Second Quarter 2015 Financial Results

7/28/2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United Therapeutics Corporation (NASDAQ: UTHR ) today announced its financial results for the second quarter ended June 30, 2015. "Orenitram ®  sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeu... [Comments]

CollPlant Names Shomrat Shurtz Senior Director of Business Development

7/28/2015
NESS ZIONA, Israel , July 28, 2015 CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced that Shomrat Shurtz has been appointed Senior Director of Business Development, effective September 20, 2015.      (Photo: http://photos.prn... [Comments]

Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan

7/28/2015
SINGAPORE , July 28, 2015  Faced with increasing challenges such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself. With few existing therapies capable of curing or significantly changing the course of a disease, healthcare providers are starting to look towards regenerativ... [Comments]

Amgen Announces Webcast of 2015 Second Quarter Financial Results

7/27/2015
THOUSAND OAKS, Calif. , July 27, 2015  Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway ,... [Comments]

Capella Healthcare Announces Agreement With Medical Properties Trust, Inc.

7/27/2015
CHICAGO and FRANKLIN, Tenn. , July 27, 2015  Capella Healthcare, Inc. ("Capella"), a privately-owned  premier provider of health care services and one of the largest for-profit hospital companies in the U.S., today announced that its parent company and sole stockholder, Capella Holdings, Inc., has signed a definitive agreement with Medical Properties Trust, I... [Comments]

Quest PharmaTech Closes $1,000,000 Private Placement

7/27/2015
EDMONTON , July 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today provides the following financial update. Quest announces that it has closed a $1,000,000 unit offering private placement.  This financing is a non-brokered private placement of 16,666,6... [Comments]

[previous] [next]
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... By creating a powerful new gene regulation system called ... increase the expression of multiple genes simultaneously and precisely ... in both mouse and human cells as well as ... that will be very useful for studying many biological ...
... fluxes in carbon sequestration, and other forest ecosystem functions. ... collected woody plant traits. Yet, the traditional method to ... have developed a new, resourceful way to take repeated ... are metal straps that wrap around a tree trunk ...
... Access to Research Careers) Program has announced the travel ... Exercises Workshop at the Marine Biological Laboratory in Woods ... to graduate students, postdocs and new assistant professors who ... successful grant application. This year MARC conferred 15 awards ...
Cached Biology News:Novel approach to gene regulation can activate multiple genes simultaneously 2New technique for measuring tree growth cuts down on research time 2New technique for measuring tree growth cuts down on research time 3
Request Info...
... , Maintenance 112 days/each , ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ml ... ml blood (~50 ml serum) x1 each , ...
... 500 g protein in 200 l ... whole cell lysate; Abelson transformed macrophage cells, ... blotting positive control, should be ... should be minimized, sample vial ...
muscle actin (HUC1-1)...
Biology Products:
(Date:7/28/2015)... ZIONA, Israel , ... Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing ... products, today announced that Shomrat Shurtz has been ... 20, 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... over 25 years of experience in marketing, regulatory ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
(Date:7/27/2015)... July 27, 2015   Inocucor Technologies Inc ... biological accelerators for farmers, has received a notice ... Office for its patent application to protect Inocucor ... growth and enhance yields on farms and in ... Inocucor,s live IN-M1 microbial consortium and its fermentation ...
(Date:7/27/2015)... , July 27, 2015 The ... the winners of its annual Klerman and Freedman ... scientists who have been supported by NARSAD Young ... to pursue innovative ideas in neurobiological and psychosocial ... concept for the early detection, treatment, prevention and ...
Breaking Biology Technology:CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... May 26 iKnowMed™, the US ... eleven EHR vendors selected to participate in the fourth American ... be held June 5-7 at the 2010 ASCO ... integrated oncology company uniting the nation,s largest network of community-based ...
... JERUSALEM , May 26, 2010 , ... - Study Data Shows ORMD-0801 Resulted in ... ... announced today that the,paper entitled, "Open-label study to assess the safety and pharmacodynamics,of five ...
... May 26 Advanced Life Sciences ... company engaged in the discovery, development and commercialization of novel ... diseases, today announced positive results from in vitro ... Restanza™ (cethromycin), its novel oral antibiotic, against the species of ...
Cached Biology Technology:US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 2US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 3US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 4US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 5Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5